SP-26 is a ketamine-based injectable dissolvable implant that’s being evaluated for the treatment of chronic pain and fibromyalgia.
SP-26, Silo Pharma’s time-released, dose-controlled formulation of ketamine, maintained its structural stability as an implantable treatment in a pre-clinical research study, the company said.
The study involves analytical testing services and small-batch proof-of-concept extrusion trials to determine drug release and stability.
In recent testing, SP-26 polymer implants were blended with ketamine hydrochloride (ketamine HCL) in two loadings: 20% and 40%. Measurements and analysis demonstrated that the drug was successfully loaded into the engineered particles to encapsulate the implantable treatment, according to Silo Pharma.
The structural stability and integrity of both the 20% and 40% loaded implants were maintained, with no leakage, degradation or discoloration, according to the company.
“Implantable drug-delivery systems like SP-26 may provide sustained drug delivery for prolonged periods of time, which is critical for the treatment of chronic pain conditions,” said Eric Weisblum, CEO of Silo. “We believe the initial testing provided sufficient validation of the delivery system for SP-26 and accordingly, our focus has shifted to testing of the ketamine formulation to measure drug dissolution and time-release action.”
SP-26 is a ketamine-based injectable dissolvable implant that’s being evaluated for the treatment of chronic pain and fibromyalgia.
Weisblum asserted that conventional oral and injectable drugs typically provide peaks of concentration in blood followed by diminished concentration that falls outside of the therapeutic window.
“Silo believes that implantable drug-delivery systems can offer a superior delivery alternative for sustained relief from chronic pain,” the developmental-stage biopharmaceutical company said in a news release.